You diagnosis a 68 year old male with Chronic Obstructive Pulmonary Disorder (COPD) in your clinic. The patient falls into GOLD Group A. Which class of medications should your consider prescribing per the GOLD therapy recommendations?

Rationale: A. High dose inhaled corticosteroids are generally avoided as initial monotherapy in COPD due to an increased risk of developing pneumonia and their limited effect on non-eosinophilic airway inflammation. In GOLD Group A, the focus is on symptom management via bronchodilation rather than suppressing a specific inflammatory pathway. Standard guidelines reserve corticosteroids for patients with high exacerbation risks or significant blood eosinophilia. B. Leukotriene modifiers do not have an established role in the primary management of COPD and are not included in the GOLD treatment algorithms. While they are useful for asthma, the pathophysiology of COPD involves different inflammatory cells and mediators that do not respond effectively to leukotriene receptor blockade. A SABA alone is insufficient for patients requiring consistent maintenance of airway patency. C. The combination of a LABA and ICS is not indicated for Group A patients, who are characterized by low symptom scores and a low risk of exacerbations. Inhaled corticosteroids are associated with side effects such as oral candidiasis and bone density loss, making them inappropriate for mild disease stages. Initial therapy should prioritize long-acting bronchodilators to improve lung function and reduce the frequency of rescue inhaler use. D. For patients in GOLD Group A, the recommendation is a bronchodilator, which can be either a short-acting or a long-acting agent depending on the patient's symptom persistence. A long-acting muscarinic antagonist (LAMA) provides sustained bronchodilation by blocking acetylcholine at M3 receptors, which is highly effective in COPD. A SABA is also provided to the patient for the immediate relief of acute breakthrough dyspnea.